Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia

Leukemia Research

Volumn 28, Issue 5, 2004, Pages 449-455

  Suvannasankha, Attaya ^a   Minderman, Hans ^a   O'Loughlin, Kieran L ^a   Sait, Sheila N J ^a   Stewart, Carleton C ^a   Greco, William R ^a   Baer, Maria R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

ABC; Acute myeloid leukemia; AML; ARA; ATP binding cassette; CBF; Complete remission; Core binding factor; CR; DFS; Disease free survival; MDR; MRP 1; Multidrug resistance; Multidrug resistance protein 1; Natural killer; NK; P glycoprotein; Pgp

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD56 ANTIGEN; CELL ADHESION MOLECULE; CORE BINDING FACTOR; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN SUBUNIT; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT FAILURE;

ADULT; ANTIGENS, CD56; CORE BINDING FACTOR ALPHA SUBUNITS; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE REARRANGEMENT; HUMANS; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; P-GLYCOPROTEIN; TRANSCRIPTION FACTORS;

EID: 1842455186     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.09.003     Document Type: Article

References (44)

1. Berger R., Bernheim A., Ochoa-Noguera M.E., Daniel M.T., Valensi F., Sigaux F.et al. Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: a study of 343 patients. Cancer Genet. Cytogenet. 28:1987;293-299.
2. Keating M.J., Smith T.L., Kantarjian H., Cork A., Walters R., Trujillo J.M.et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia. 2:1988;403-412.
3. Schiffer C.A., Lee E.J., Tomiyasu T., Wiernik P.H., Testa J.R. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 73:1989;263-270.
4. Dastugue N., Payen C., Lafage-Pochitaloff M., Bernard P., Leroux D., Huguet-Rigal F.et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia. 9:1995;1491-1498.
5. Bloomfield C.D., Lawrence D., Byrd J.C., Carroll A., Pettenati M.J., Tantravahi R.et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 58:1998;4173-4179.
6. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C.et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with denovo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 100:2002;4325-4336.
7. Westendorf J.J., Yamamoto C.M., Lenny N., Downing J.R., Selsted M.E., Hiebert S.W. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol. Cell Biol. 18:1998;322-333.
8. Liu P., Tarle S.A., Hajra A., Claxton D.F., Marlton P., Freedman M.et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 261:1993;1041-1044.
9. Hurwitz C.A., Raimondi S.C., Head D., Krance R., Mirro J., Kalwinsky D.K.et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood. 80:1992;3182-3188.
10. Baer M.R., Stewart C.C., Lawrence D., Arthur D.C., Byrd J.C., Davey F.R.et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood. 90:1997;1643-1648.
11. Ferrara F., Morabito F., Martino B., Specchia G., Liso V., Nobile F.et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J. Clin. Oncol. 18:2000;1295-1300.
12. Raspadori D., Damiani D., Lenoci M., Rondelli D., Testoni N., Nardi G.et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 15:2001;1161-1164.
13. Lanier L.L., Testi R., Bindi J., Phillips J.H. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J. Exp. Med. 169:1989;2233-2238.
14. Klimecki W.T., Futscher B.W., Grogan T.M., Dalton W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 83:1994;2451-2458.
15. Egashira M., Kawamata N., Sugimoto K., Kaneko T., Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 93:1999;599-606.
16. Leith C.P., Kopecky K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S.et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 94:1999;1086-1099.
17. Leith C.P., Kopecky K.J., Godwin J., McConnell T., Slovak M.L., Chen I.M.et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group. Blood. 89:1997;3323-3329.
18. Pearson L., Leith C.P., Duncan M.H., Chen I.-M., McConnell T., Trinkaus K.et al. Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia. Leukemia. 10:1996;1274-1282.
19. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 93:1999;1658-1667.
20. Kuss B.J., Deeley R.G., Cole S.P.C., Willman C.L., Kopecky K.J., Wolman S.R.et al. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet. 343:1994;1531-1534.
21. Kuss B.J., O'Neill G.M., Eyre H., Doggett N.A., Callen D.F., Davey R.A. ARA, a novel ABC transporter, is located at 16p13.1, is deleted in inv(16) leukemias, and is shown to be expressed in primitive hematopoietic precursors. Genomics. 51:1998;455-458.
22. van der Kolk D.M., Vellenga E., van der Veen A.Y., Noordhoek L., Timmer-Bosscha H., Ossenkoppele G.J.et al. Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity. Blood. 95:2000;3514-3519.
23. Tosi P., Visani G., Ottaviani E., Testoni N., Pellacani A., Tura S. Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro. Eur. J. Haematol. 60:1998;161-165.
24. Ross D.D., Karp J.E., Chen T.T., Doyle L.A. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 96:2000;365-368.
25. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 100:2002;2292-2302.
26. Mancini M., Cedrone M., Diverio D., Emanuel B., Stul M., Vranckx H.et al. Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients. Leukemia. 14:2000;364-368.
27. Baer M.R., George S.L., Dodge R.K., O'Loughlin K.L., Minderman H., Caligiuri M.A.et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 100:2002;1224-1232.
28. Den Boer M.L., Zwaan C.M., Pieters R., Kazemier K.M., Rottier M.M., Flens M.J.et al. Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia. Leukemia. 11:1997;1078-1085.
29. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H.et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61:2001;3458-3464.
30. Scheffer G.L., Maliepaard M., Pijnenborg A.C.L.M., van Gastelen M.A., de Jong M.C., Schroeijers A.B.et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res. 60:2000;2589-2593.
31. Minderman H., Suvannasankha A., O'Loughlin K.L., Scheffer G.L., Scheper R.J., Robey R.W.et al. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry. 48:2002;59-65.
32. Dalton W.S., Durie B.G., Alberts D.S., Gerlach J.H., Cress A.E. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res. 46:1986;5125-5130.
33. Marsh W., Sicheri D., Center M.S. Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res. 46:1986;4053-4057.
34. Hazlehurst L.A., Foley N.E., Gleason-Guzman M.C., Hacker M.P., Cress A.E., Greenberger L.W.et al. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res. 59:1999;1021-1028.
35. Young I.T. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J. Histochem. Cytochem. 25:1977;935-941.
36. Baer M.R., Christiansen N.P., Frankel S.R., Brunetto V.L., Mrózek K., Bloomfield C.D.et al. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. Semin. Oncol. 20(Suppl. 8):1993;6-12.
37. Kolitz J.E., George S.L., Hurd D., Hoke E., Dodge R.K., Caligiuri M.A.et al. Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients with acute myeloid leukemia (AML) <60 years old: preliminary results of CALGB 9621. Blood. 94:1999;384a.
38. Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D.et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 8:1990;813-819.
39. SAS Institute. SAS/STAT user's guide, version 8. Cary, NC; 1999.
40. Minitab, Inc. MINITAB statistical software user's guide, rel. 13; 2000.
41. Leith C.P., Chen I.M., Kopecky K.J., Appelbaum F.R., Head D.R., Godwin J.E.et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood. 86:1995;2329-2342.
42. Lutterbach B., Sun D., Schuetz J., Hiebert S.W. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Mol. Cell Biol. 18:1998;3604-3611.
43. Braess J., Jahns-Streubel G., Schoch C., Haase D., Haferlach T., Fiegl M.et al. Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia. Br. J. Haematol. 113:2001;975-982.
44. Hazlehurst L.A., Damiano J.S., Buyuksal I., Pledger W.J., Dalton W.S. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 19:2000;4319-4327.